Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + cyclophosphamide + paclitaxel + carboplatin + pembrolizumab
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen used in oncology, typically for the treatment of certain advanced or aggressive cancers. The regimen combines four cytotoxic chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel, and carboplatin) with pembrolizumab, an immune checkpoint inhibitor. Epirubicin and cyclophosphamide are anthracycline and alkylating agents respectively; paclitaxel is a taxane that stabilizes microtubules; carboplatin is a platinum-based DNA crosslinking agent; pembrolizumab is a monoclonal antibody targeting PD-1 to enhance anti-tumor immune responses[6][5][2]. This combination leverages both direct cytotoxic effects on cancer cells and activation of the immune system against tumors.
- Other names
- ECPC+Pembrolizumabepirubicin/cyclophosphamide/paclitaxel/carboplatin/pembrolizumab
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on epirubicin + cyclophosphamide + paclitaxel + carboplatin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + cyclophosphamide + paclitaxel + carboplatin + pembrolizumab.